A Pilot study comparing recombinant erythropoietin alone with erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor for treatment of the anemia of prematurity. Recombinant human erythropoietin to prevent and treat the anemia of prematurity. Neutrophil pool sizes and granulocyte colony-stimulating factor production in human mid-trimester fetuses. Maternal and umbilical serum concentrations of granulocyte colony-stimulating factor and its mRNA during clinical chorioamnionitis. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo controlled trial. The Pharmacologic stabilitly of human recombinant erythropoietin in commonly used neonatal intravenous solutions. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution. Effects of recombinant granulocyte-macrophage colony-stimulating factor on the capacity of mononuclear cells from preterm infants to generate interleukin-6 and granulocyte colony-stimulating factor. The effect of erythropoietin on the transfusion requirements of preterm infants < (or equal to) 750 grams: a randomized, double-blind, placebo-controlled study. Serum erythropoietin concentrations fail to increase following significant phlebotomy losses in ill, preterm infants. Erythropoietin to prevent and treat the anemia of prematurity. Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. Endothelin concentrations in preterm infants treated with human recombinant erythropoietin. Consistent approaches to procedures and practices in neonatal hematology. Journal of pediatric hematology/oncology. Effects of granulocyte-colony stimulating factor on term and preterm cord blood neutrophil adhesive molecules. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birthweight: a multi-center, randomized controlled trial. 
Reticulocyte hemoglobin content: an improved technique to measure iron suffiicient erythropoiesis in preterm infants.Management of anemia of prematurity using human recomginant erythropoietin.Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.
Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Erythropoietin and hypoxia inducible factor-1 expression in the mid-trimester human fetus. Transfusion Alternatives to Transfusion Medicine. Changing transfusion practices in pediatrics. Anemia of the premature infant: a two year study of the response to iron medication. 
Neurodevelopmental outcome and growth at 18-22 months corrected age in extremely low birth weight infants treated with early erythropoietin and iron.Long acting erythropoietin: clinical studies and potential uses in neonates.Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron.Single-dose darbepoetin administrations to anemic preterm neonates.Renal excretion of darbepoetin following single dose administration.Intravenous administration of darbepoetin to NICU patients.Erythropoietin concentrations and neurodevelopmental outcome in preterm infants.Darbepoetin alfa: Pharmocokinetics and clinical use in neonates.Elevated erythropoietin mRNA and protein concentrations in the developing human eye.Epithelial cells in fetal intestine produce chemerin to recruit macrophages.Developmental changes in circulating IL-8/CXCL8 isoforms in neonates.Current controversies in the management of anemia of prematurity.
0 kommentar(er)
